MRK Factor-Based Stock Analysis - Peter Lynch July 09, 2025 — 09:03 am EDT Written by John Reese for Validea -> Below is Validea's guru fundamental report for MERCK & CO INC (MRK).

MRK Quantitative Stock Analysis - Peter Lynch July 08, 2025 — 09:08 am EDT Written by John Reese for Validea -> Below is Validea's guru fundamental report for MERCK & CO INC (MRK).

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

Cantor Fitzgerald’s analysis suggests the Verona acquisition would enhance Merck’s top-line growth profile, even without considering potential revenue synergies from the combined operations.

The downgrade comes as Merck plans to acquire Verona Pharma for $107 per share, representing approximately a 23% premium to the stock’s previous trading price.

EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.

Dow, S&P500 hold gains as traders weigh Trump’s tariffs, Fed’s path. Watch Starbucks, Verona, AES as sector shifts create ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Find the latest Merck & Co., Inc. (MRK) stock quote, history, news and other vital information to help you with your stock trading and investing.

The blue-chip index FTSE 100 rose about 0.2% and the British pound declined 0.1% against the dollar to over 1.3580. DAX index in Germany gained 1.3%, the CAC 40 in France rose 1.4%.

The uncertainty over the impact of President Trump’s tariff threats on trading partners has Broward County’s maritime ...

Two art-market analysts find a bear market for auctions sales of art: For three seasons now, 50% of artworks resold at auction had negative returns, the worst market this century.